MNKD MannKind Corporation - Common Stock
$4,26
Precio · Ago 19, 2026
Fundamentales a fecha de Ago 5, 2026
Rango 52S
$2–$7
47% of range
Calificación del Analista
BUY
14 analysts
Precio Objetivo
$8
+87% upside
P/E (TTM)
212.9
ROE
-11.1%
Margen de Beneficio Neto
1.7%
Acerca de MannKind Corporation - Common Stock Descripción general de la empresa de Wikipedia
MannKind Corporation is a biopharmaceutical company focusing on the discovery, development, and commercialization of therapeutic products for diseases such as diabetes and pulmonary arterial hypertension. Based in Danbury, Connecticut, the company was founded in February 1991.
Leer más
MannKind Corporation is a biopharmaceutical company focusing on the discovery, development, and commercialization of therapeutic products for diseases such as diabetes and pulmonary arterial hypertension. Based in Danbury, Connecticut, the company was founded in February 1991.
MannKind Corporation was named after its founder, Alfred E. Mann.
History
Founded in February 1991, the company's present form is a result of a 2003 merger of three companies owned by Alfred E. Mann: Pharmaceutical Discovery Corporation (PDC), the cancer vaccine developer CTL ImmunoTherapies, Inc., and its sister company Allecure Corp, which was developing an allergy vaccine technology. Pharmaceutical Discovery was purchased in 2001 from Solomon Steiner; with that purchase MannKind acquired the Technosphere molecule and Medtone inhaler, upon which was developed its lead product, Afrezza (inhalable insulin).
The FDA approved Afrezza on June 27, 2014.
On August 11, 2014 MannKind entered into an exclusive global licensing agreement with Sanofi for Afrezza sales. Under the agreement, MannKind received $150 million cash from Sanofi, in exchange for sharing profits and losses of sales of Afrezza, with 65% for Sanofi and 35% for MannKind. On January 5, 2016, MannKind Corporation announced the termination of the license and collaboration agreement with Sanofi. By December 2017, the company had lost 11% of its trading volume due to the poor sales.
In March 2020, the company announced it was working with fellow pharmaceutical company Immix Biopharma to try to develop an inhalable treatment for acute respiratory distress syndrome, a lung disease.
Products and product candidates
The firm has developed Afrezza a rapid-acting insulin peaking 12 to 15 minutes after inhalation and exiting the body within 2–3 hours. The inhalation technology uses a miniature, breath-powered inhaler in combination with single-use cartridges containing pre-metered doses. Initial pharmacokinetic studies were followed by studies of safety and efficiency involving Technosphere formulations of different therapeutic proteins.
Leadership
Mann was chief executive officer until January 12, 2015 when Hakan Edstrom became CEO and Mann transitioned to executive chairman.
In November 2015, Hakan Edstrom stepped down as CEO and president. Company founder Alfred Mann stepped in as interim CEO on November 19, 2015. In 2016, Matthew Pfeffer was appointed CEO of MannKind, and served as both CEO and CFO. In May 2017, Michael Castagna was named CEO of the company.
Facilities
MannKind has a large corporate office in Westlake Village, California. The Afrezza manufacturing facility is in Danbury, Connecticut. In 2022, the company moved its official headquarters to Danbury.
Fuente: Wikipedia (Inglés), CC BY-SA 4.0 · Ver en Wikipedia ↗
MNKD Instantánea de la Acción Precio, capitalización bursátil, P/E, BPA, ROE, deuda/capital, rango de 52 semanas
Precio
$4.26
Capitalización Bursátil
$1.31B
P/E (TTM)
212.9
BPA (TTM)
$0.02
Ingresos (TTM)
$349M
Rendimiento div.
—
ROE
-11.1%
Deuda/Capital
—
Rango 52S
$2 – $7
MNKD Gráfico del Precio de la Acción OHLCV diario con indicadores técnicos — desplace, amplíe y personalice su vista
Configure
Rendimiento a 10 años Tendencias de ingresos, beneficio neto, márgenes y BPA
Ingresos y Beneficio Neto
$349M
2016-12-31
→
2025-12-31
BPA
$0.02
2016-12-31
→
2025-12-31
Flujo de caja libre
$14M
2018-12-31
→
2025-12-31
Márgenes
1.7%
Valoración Ratios P/E, P/S, P/B, EV/EBITDA: ¿está la acción cara o barata?
Métrica
Tendencia a 5 años
MNKD
Mediana de Pares
P/E (TTM)
212.9
—
P/S (TTM) (P/V (TTM))
3.8
10.7
P/B (P/C)
-25.7
5.2
Price / FCF (Precio / FCF)
95.7
—
Rentabilidad Márgenes brutos, operativos y netos; ROE, ROA, ROIC
Métrica
Tendencia a 5 años
MNKD
Mediana de Pares
Operating Margin (Margen Operativo)
11.1%
—
Net Profit Margin (Margen de Beneficio Neto)
1.7%
-140.3%
ROA
0.99%
-44.7%
ROE
-11.1%
-51.5%
ROIC
-316.9%
—
Salud financiera Deuda, liquidez, solvencia — solidez del balance general
Métrica
Tendencia a 5 años
MNKD
Mediana de Pares
Current Ratio (Ratio corriente)
1.7
9.5
Quick Ratio (Ratio Rápido)
1.2
—
Crecimiento Crecimiento de ingresos, BPA y beneficio neto: interanual, CAGR a 3 años, CAGR a 5 años
Métrica
Tendencia a 5 años
MNKD
Mediana de Pares
Revenue YoY (Ingresos interanuales)
22.2%
—
Revenue CAGR 3Y (Ingresos CAGR 3A)
51.8%
—
Revenue CAGR 5Y (Ingresos CAGR 5A)
39.9%
—
EPS YoY (EPS interanual)
-80.0%
—
Net Income YoY (Beneficio Neto interanual)
-78.8%
—
Eficiencia de capital Rotación de activos, rotación de inventario, rotación de cuentas por cobrar
Métrica
Tendencia a 5 años
MNKD
Mediana de Pares
MNKD Consenso de analistas Opiniones de analistas alcistas y bajistas, precio objetivo a 12 meses, potencial alcista
COMPRA
14 analistas
- Compra fuerte 4 28,6%
- Compra 8 57,1%
- Mantener 2 14,3%
- Venta 0 0,0%
- Venta fuerte 0 0,0%
Precio objetivo a 12 meses
8 analistas · 2026-08-17
Mediana
$7.50
← Por Debajo de Todos los Objetivos
$4.26
Mín
$4.75
Máx
$13.00
Objetivo mediano
$7.50
+76,2%
Objetivo medio
$7.97
+87,2%
Historial de Ganancias EPS real vs estimado, sorpresa %, tasa de aciertos, próxima fecha de resultados
Sorpresa Media
-0.03%
| Período | EPS Actual | EPS est. | Sorpresa |
|---|---|---|---|
| 30 de junio de 2026 | $-0.06 | $-0.00 | -0.06% |
| 31 de marzo de 2026 | $-0.05 | $-0.00 | -0.05% |
| 31 de diciembre de 2025 | $-0.05 | $0.01 | -0.06% |
| 30 de septiembre de 2025 | $0.07 | $0.02 | 0.05% |
| 30 de junio de 2025 | $0.00 | $0.05 | -0.05% |
| 31 de marzo de 2025 | $0.04 | $0.04 | -0.00% |
Comparación de pares (subindustria GICS) Métricas clave frente a competidores del sector
| Ticker | Capitalización Bursátil | P/E | Ingresos interanuales | Margen Neto | ROE | Margen Bruto |
|---|---|---|---|---|---|---|
| MNKD | $1.75B | 283.5 | 22.2% | 1.7% | -11.1% | — |
| NVAX | $1.09B | 2.6 | 64.7% | 39.2% | -977.1% | — |
| INBX | $1.15B | -8.7 | 550.0% | -10773.5% | -365.9% | — |
| GLUE | $1.03B | — | 63.5% | -31.2% | -15.4% | — |
| MGTX | $645M | -5.6 | 144.6% | -140.3% | 8062.2% | — |
| CRVS | $575M | -14.5 | — | — | -21.6% | — |
| REPL | $633M | -2.3 | — | — | -146.2% | — |
| VOR | $506M | -0.2 | — | — | 83.4% | — |
| SANA | $1.09B | -4.2 | — | — | -172.3% | — |
| SVRA | $1.23B | -11.4 | — | — | -73.4% | — |
Fundamentales Completos Todas las métricas por año — estado de resultados, balance general, flujo de caja
Estado de resultados 16
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $349M | $286M | $199M | $100M | $75M | $65M | $63M | $28M | $12M | $175M | $0 | $0 | |
| Cost of Revenue | $27M | $17M | $21M | $16M | $17M | $15M | $20M | $19M | $17M | $17M | $65M | · | |
| SG&A Expense | $144M | $94M | $94M | $91M | $32M | $25M | $75M | $80M | $75M | $47M | $41M | $79M | |
| Operating Expenses | $88M | $77M | $63M | $57M | $39M | $25M | $108M | $104M | $120M | $107M | $345M | $180M | |
| Operating Income | $39M | $73M | $9M | $-64M | $-47M | $-48M | $-45M | $-77M | $-108M | $67M | $-345M | $-180M | |
| Interest Expense | · | · | $15M | $15M | $15M | · | · | · | · | · | $24M | $20M | |
| Interest Income | $8M | $13M | $6M | $3M | $112.0K | $167.0K | $997.0K | $501.0K | $293.0K | $85.0K | $18.0K | $9.0K | |
| Other Non-op | $-1M | $32.0K | $122.0K | $-102.0K | $-239.0K | $23.0K | $-926.0K | $-437.0K | $13.0K | $-597.0K | $1M | $2M | |
| Pretax Income | $1M | $31M | $-10M | $-87M | $-81M | $-57M | $-52M | $-87M | $-117M | $126M | $-368M | $-198M | |
| Income Tax | $-4M | $3M | $2M | $0 | $0 | $-218.0K | $0 | $240.0K | $51.0K | $0 | $0 | $0 | |
| Net Income | $6M | $28M | $-12M | $-87M | $-81M | $-57M | $-52M | $-87M | $-117M | $126M | $-368M | $-198M | |
| EPS (Basic) | $0.02 | $0.10 | $-0.04 | $-0.34 | $-0.32 | $-0.26 | · | $-0.60 | $-1.13 | $1.37 | $-4.54 | $-2.57 | |
| EPS (Diluted) | $0.02 | $0.10 | $-0.04 | $-0.34 | $-0.32 | $-0.26 | · | $-0.60 | $-1.13 | $1.36 | $-4.54 | $-2.57 | |
| Shares (Basic) | 305,639,000 | 274,415,000 | 267,014,000 | 257,092,000 | 249,244,000 | 222,585,000 | · | 144,136,000 | 104,245,000 | 92,053,000 | 81,233,000 | 77,045,000 | |
| Shares (Diluted) | 314,112,000 | 283,844,000 | 267,014,000 | 257,092,000 | 249,244,000 | 222,585,000 | · | 144,136,000 | 104,245,000 | 92,085,000 | 81,233,000 | 77,045,000 | |
| EBITDA | $39M | $73M | $9M | $-64M | $-47M | $-48M | $-45M | $-77M | $-106M | · | $-334M | $-170M |
Balance general 28
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $75M | $46M | $238M | $70M | $124M | $67M | $30M | $71M | $44M | $23M | $59M | $121M | |
| Short-term Investments | $96M | $151M | $57M | $101M | $80M | $0 | $20M | · | · | · | · | · | |
| Receivables | $38M | $12M | $15M | $17M | $5M | $4M | $4M | $4M | $3M | $302.0K | $23.0K | $50M | |
| Inventory | $35M | $28M | $29M | $22M | $7M | $5M | $4M | $4M | $3M | $2M | · | $10M | |
| Prepaid Expense | $47M | $31M | $35M | $25M | $3M | $3M | $3M | $3M | $3M | $4M | $4M | $20M | |
| Current Assets | $292M | $268M | $373M | $235M | $219M | $79M | $61M | $82M | $57M | $77M | $77M | $201M | |
| PP&E (Net) | $82M | $85M | $84M | $45M | $37M | $26M | $27M | $26M | $27M | $29M | $49M | $192M | |
| PP&E (Gross) | $196M | $192M | $186M | $144M | $134M | $123M | $122M | $126M | $128M | $129M | $168M | $310M | |
| Accum. Depreciation | $114M | $107M | $102M | $99M | $98M | $97M | $95M | $100M | $101M | $100M | $120M | $118M | |
| Goodwill | $68M | $2M | $2M | $2M | · | · | · | · | · | · | · | · | |
| Intangibles | $5M | $5M | $1M | $1M | · | · | · | · | · | · | · | · | |
| Other Non-current Assets | $20M | $27M | $7M | $10M | $8M | $3M | $6M | $249.0K | $437.0K | $648.0K | $1M | $848.0K | |
| Total Assets | $792M | $394M | $475M | $295M | $321M | $109M | $94M | $108M | $85M | $107M | $126M | $394M | |
| Accounts Payable | $9M | $7M | $10M | $11M | $7M | $6M | $5M | $5M | $7M | $3M | $16M | $7M | |
| Accrued Liabilities | $65M | $40M | $42M | $36M | $27M | $20M | $16M | $15M | $12M | $8M | $8M | $26M | |
| Short-term Debt | · | · | · | · | · | · | $5M | · | · | · | · | · | |
| Current Liabilities | $171M | $82M | $104M | $67M | $48M | $74M | $66M | $75M | $88M | $92M | $268M | $403M | |
| Capital Leases | $11M | $12M | $4M | $5M | $1M | $1M | $3M | · | · | · | · | · | |
| Other Non-current Liabilities | · | · | · | · | $5M | · | · | · | · | · | $15M | $12M | |
| Total Liabilities | $843M | $473M | $721M | $546M | $531M | $289M | $284M | $283M | $299M | $291M | $477M | $468M | |
| Long-term Debt | $355M | $36M | $269M | $273M | $281M | $122M | $119M | $102M | $157M | · | · | · | |
| Total Debt | · | · | · | · | · | · | $5M | · | · | · | · | · | |
| Common Stock | $3M | $3M | $3M | $3M | $3M | $2M | $2M | $2M | $1M | $957.0K | $4M | $4M | |
| Retained Earnings | $-3.20B | $-3.20B | $-3.23B | $-3.22B | $-3.13B | $-3.05B | $-2.99B | $-2.94B | $-2.85B | $-2.74B | $-2.86B | $-2.49B | |
| AOCI | $115.0K | $1M | · | · | · | · | $-19.0K | $-19.0K | $-18.0K | $-24.0K | $-20.0K | $-14.0K | |
| Stockholders' Equity | $-51M | $-79M | $-246M | $-251M | $-209M | $-180M | $-191M | $-175M | $-215M | $-184M | $-350M | $-74M | |
| Liabilities + Equity | $792M | $394M | $475M | $295M | $321M | $109M | $94M | $108M | $85M | $107M | $126M | $394M | |
| Shares Outstanding | 307,832,587 | 302,959,782 | 270,034,495 | 263,793,305 | 251,477,562 | 242,117,089 | 211,787,573 | 187,029,967 | 119,053,414 | 95,680,831 | 85,734,188 | 406,059,089 |
Flujo de Efectivo 18
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $12M | $7M | $5M | $3M | $2M | $2M | $972.0K | $3M | $2M | $2M | $11M | $10M | |
| Stock-based Comp | $24M | $21M | $18M | $13M | $12M | $7M | $6M | $7M | $5M | $5M | $9M | $49M | |
| Deferred Tax | $-19M | $4M | $7M | $-10M | $-20M | $-5M | $-5M | $-11M | $-260M | $48M | $-80M | $-66M | |
| Amort. of Intangibles | $4M | · | · | · | · | · | · | · | · | · | · | · | |
| Restructuring | · | · | · | · | · | · | · | · | · | $2M | $6M | $2M | |
| Other Non-cash | · | · | · | · | · | · | · | · | $306M | · | $291M | $144M | |
| Operating Cash Flow | $18M | $43M | $34M | $-81M | $-62M | $-28M | $-88M | $-38M | $-65M | $-78M | $-57M | $4M | |
| CapEx | $5M | $10M | $42M | $8M | $11M | $801.0K | $3M | $354.0K | · | $1M | $10M | $24M | |
| Investing Cash Flow | $-305M | $-97M | $-2M | $5M | $-152M | $15M | $-23M | $-234.0K | $17M | $-1M | · | · | |
| Debt Issued | · | · | · | · | · | $5M | · | · | · | · | · | $20M | |
| Net Debt Issued | · | · | · | · | · | $5M | · | · | · | · | · | · | |
| Stock Issued | · | · | · | · | · | · | · | · | $564.0K | $893.0K | $28M | · | |
| Net Stock Activity | · | · | · | · | · | · | · | · | $564.0K | · | $28M | · | |
| Financing Cash Flow | $315M | $-137M | $137M | $21M | $270M | $50M | $70M | $61M | $74M | $43M | · | · | |
| Net Change in Cash | $29M | $-191M | $169M | $-54M | $57M | $37M | $-41M | $23M | $25M | $-36M | $-62M | $50M | |
| Taxes Paid | $2M | $4M | · | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | $14M | $33M | $-8M | $-88M | $-73M | $-29M | $-91M | $-38M | · | · | $-68M | $-20M | |
| Levered FCF | · | · | $-26M | $-98M | · | · | · | · | · | · | $-92M | · |
Rentabilidad 7
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 11.1% | 25.4% | 4.4% | -64.3% | -62.3% | -73.6% | -70.8% | -274.9% | -921.1% | · | · | · | |
| Net Margin | 1.7% | 9.7% | -6.0% | -87.6% | -107.3% | -87.9% | -82.3% | -312.2% | -999.0% | · | · | · | |
| Pretax Margin | 0.40% | 10.7% | -5.2% | -87.6% | -107.3% | -88.2% | -82.3% | -311.3% | -998.6% | · | · | · | |
| EBITDA Margin | 11.1% | 25.4% | 4.4% | -64.3% | -62.3% | -73.6% | -70.8% | -274.9% | -905.8% | · | · | · | |
| ROA | 0.99% | 6.3% | -3.1% | -28.4% | -37.7% | -56.6% | -51.5% | -90.5% | -122.4% | · | -141.5% | -60.8% | |
| ROE | -11.1% | -19.1% | 4.8% | 35.8% | 41.1% | 31.2% | 27.7% | 45.7% | 58.9% | · | 173.8% | 379.7% | |
| ROIC | -316.9% | -83.2% | -4.1% | 25.6% | 22.5% | 26.5% | 24.0% | 43.9% | 50.4% | · | 98.4% | · |
Liquidez y Solvencia 4
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.7 | 3.3 | 3.6 | 3.5 | 4.5 | 1.1 | 0.9 | 1.1 | 0.7 | · | 0.3 | 0.5 | |
| Quick Ratio | 1.2 | 2.6 | 3.0 | 2.8 | 4.3 | 1.0 | 0.8 | 1.0 | 0.5 | · | 0.2 | 0.4 | |
| Debt / Equity | · | · | · | · | · | · | -0.0 | · | · | · | · | · | |
| Interest Coverage | · | · | 0.6 | -6.7 | · | · | · | · | · | · | -14.3 | -8.8 |
Eficiencia 3
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.6 | 0.7 | 0.5 | 0.3 | 0.4 | 0.6 | 0.6 | 0.3 | 0.1 | · | 0.0 | · | |
| Inventory Turnover | 0.8 | 0.6 | 0.8 | 1.1 | 2.8 | 3.3 | 5.2 | 6.2 | 6.9 | · | · | · | |
| Receivables Turnover | 13.9 | 21.4 | 12.6 | 9.3 | 16.4 | 16.9 | 16.7 | 8.2 | 7.6 | · | 0.0 | · |
Tasas de Crecimiento 5
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 22.2% | 43.5% | 99.4% | 32.2% | 15.8% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 51.8% | 55.8% | 45.1% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 39.9% | · | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | -80.0% | · | · | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | -78.8% | · | · | · | · | · | · | · | · | · | · | · |
Valoración (TTM) 13
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $349M | $286M | $199M | $100M | $75M | $65M | $63M | $28M | $12M | $175M | $0 | $0 | |
| Net Income TTM | $6M | $28M | $-12M | $-87M | $-81M | $-57M | $-52M | $-87M | $-117M | $126M | $-368M | $-198M | |
| Market Cap | $1.75B | $1.95B | $983M | $1.39B | $1.10B | $758M | $273M | $198M | $276M | · | $3.11B | $10.60B | |
| Enterprise Value | · | · | · | · | · | · | $228M | · | · | · | · | · | |
| P/E | 283.5 | 64.3 | -91.0 | -15.5 | -13.7 | -12.0 | -2.0 | -1.8 | -2.1 | 2.4 | -1.6 | -10.2 | |
| P/S | 5.0 | 6.8 | 4.9 | 13.9 | 14.6 | 11.6 | 4.3 | 7.1 | 23.5 | · | · | · | |
| P/B | -34.2 | -24.7 | -4.0 | -5.5 | -5.2 | -4.2 | -1.4 | -1.1 | -1.3 | · | -8.9 | -143.7 | |
| P / Cash Flow | 95.6 | 45.8 | 28.8 | -17.2 | -17.8 | -26.9 | -3.1 | -5.3 | -4.3 | · | -54.3 | 2593.8 | |
| P / FCF | 127.5 | 59.4 | -117.8 | -15.7 | -15.0 | -26.2 | -3.0 | -5.2 | · | · | -46.0 | -529.6 | |
| EV / EBITDA | · | · | · | · | · | · | -5.1 | · | · | · | · | · | |
| EV / FCF | · | · | · | · | · | · | -2.5 | · | · | · | · | · | |
| EV / Revenue | · | · | · | · | · | · | 3.6 | · | · | · | · | · | |
| Earnings Yield | 0.35% | 1.6% | -1.1% | -6.5% | -7.3% | -8.3% | -48.8% | -56.6% | -48.7% | 42.5% | -62.6% | -9.8% |
Estado de resultados 16
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $109M | $90M | $112M | $82M | $77M | $78M | $77M | $70M | $72M | $66M | $58M | $51M | $49M | $41M | $36M | $33M | |
| Cost of Revenue | $14M | $8M | $14M | $4M | $5M | $4M | $5M | $3M | $6M | $4M | $6M | $4M | $5M | $6M | $4M | $5M | |
| SG&A Expense | $58M | $54M | $58M | $29M | $32M | $25M | $24M | $24M | $24M | $22M | $61M | $11M | $12M | $11M | $64M | $9M | |
| Operating Expenses | $30M | $92M | $-103M | $63M | $21M | $56M | $-86M | $57M | $56M | $50M | $18M | $14M | $14M | $16M | $16M | $17M | |
| Operating Income | $-350.0K | $-2M | $-8M | $19M | $5M | $22M | $26M | $13M | $17M | $17M | $8M | $5M | $2M | $-6M | $-13M | $-10M | |
| Interest Expense | · | · | · | · | · | · | · | · | $6M | $3M | · | $3M | $7M | $3M | · | $3M | |
| Interest Income | $1M | $1M | $2M | $3M | $2M | $2M | $3M | $3M | $3M | $3M | $2M | $2M | $2M | $1M | $957.0K | $663.0K | |
| Other Non-op | $-5M | $-3M | $23M | $-11M | $-4M | $-9M | $24M | $110.0K | $-18M | $-6M | $-164.0K | $318.0K | $-143.0K | $111.0K | $105.0K | $-207.0K | |
| Pretax Income | $-19M | $-16M | $-21M | $8M | $940.0K | $14M | $8M | $13M | $-2M | $11M | $3M | $2M | $-5M | $-10M | $-18M | $-14M | |
| Income Tax | $-106.0K | $253.0K | $-5M | $-204.0K | $272.0K | $459.0K | $1M | $1M | $323.0K | $264.0K | $2M | $0 | $0 | $0 | · | $0 | |
| Net Income | $-19M | $-17M | $-16M | $8M | $668.0K | $13M | $7M | $12M | $-2M | $11M | $1M | $2M | $-5M | $-10M | $-18M | $-14M | |
| EPS (Basic) | $-0.06 | $-0.05 | $-0.05 | $0.03 | $0.00 | $0.04 | $0.03 | $0.04 | $-0.01 | $0.04 | $0.01 | $0.01 | $-0.02 | $-0.04 | $-0.07 | $-0.06 | |
| EPS (Diluted) | $-0.06 | $-0.05 | $-0.05 | $0.03 | $0.00 | $0.04 | $0.03 | $0.04 | $-0.01 | $0.04 | $0.01 | $0.01 | $-0.02 | $-0.04 | $-0.07 | $-0.06 | |
| Shares (Basic) | 309,191,000 | 308,267,000 | -609,602,000 | 306,806,000 | 304,954,000 | 303,481,000 | -543,995,000 | 274,998,000 | 273,056,000 | 270,356,000 | -531,313,000 | 268,732,000 | 265,626,000 | 263,969,000 | -507,739,000 | 259,300,000 | |
| Shares (Diluted) | 309,191,000 | 308,267,000 | -629,907,000 | 311,638,000 | 311,484,000 | 320,897,000 | -598,638,000 | 284,693,000 | 273,056,000 | 324,733,000 | -586,351,000 | 323,770,000 | 265,626,000 | 263,969,000 | -507,739,000 | 259,300,000 | |
| EBITDA | · | $-2M | · | $19M | $5M | $22M | · | $13M | $17M | $17M | · | $5M | $2M | $-6M | · | $-10M |
Balance general 25
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $53M | $53M | $75M | $127M | $57M | $47M | $46M | $62M | $97M | $193M | · | $83M | $86M | $86M | · | $54M | |
| Short-term Investments | $58M | $81M | $96M | $133M | $122M | $134M | $151M | $189M | $151M | $107M | · | $58M | $58M | $80M | · | $111M | |
| Receivables | $43M | $28M | $38M | $17M | $27M | $29M | $12M | $18M | $23M | $20M | · | $22M | $28M | $20M | · | $23M | |
| Inventory | $44M | $49M | $35M | $27M | $28M | $29M | $28M | $27M | $25M | $26M | · | $27M | $25M | $22M | · | $18M | |
| Prepaid Expense | $47M | $40M | $47M | $54M | $44M | $34M | $31M | $31M | $30M | $36M | · | $36M | $33M | $15M | · | $12M | |
| Current Assets | $246M | $251M | $292M | $359M | $279M | $274M | $268M | $328M | $326M | $383M | · | $226M | $230M | $223M | · | $218M | |
| PP&E (Net) | $85M | $83M | $82M | $83M | $83M | $84M | $85M | $85M | $85M | $84M | · | $80M | $70M | $55M | · | $41M | |
| PP&E (Gross) | $203M | $198M | $196M | $195M | $194M | $192M | $192M | $192M | $190M | $186M | · | $182M | $170M | $154M | · | $140M | |
| Accum. Depreciation | $118M | $116M | $114M | $113M | $111M | $109M | $107M | $107M | $105M | $103M | · | $101M | $100M | $100M | · | $99M | |
| Goodwill | $68M | $68M | $68M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | · | $2M | $2M | $2M | · | $3M | |
| Intangibles | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $1M | $1M | · | $1M | $1M | $1M | · | $1M | |
| Other Non-current Assets | $17M | $22M | $20M | $19M | $20M | $28M | $27M | $26M | $16M | $7M | · | $8M | $8M | $16M | · | $17M | |
| Total Assets | $732M | $744M | $792M | $495M | $412M | $410M | $394M | $464M | $444M | $481M | · | $320M | $313M | $298M | · | $294M | |
| Accounts Payable | $11M | $16M | $9M | $7M | $10M | $5M | $7M | $6M | $10M | $7M | · | $17M | $17M | $14M | · | $10M | |
| Accrued Liabilities | $61M | $59M | $65M | $31M | $31M | $40M | $40M | $37M | $41M | $42M | · | $32M | $37M | $33M | · | $30M | |
| Current Liabilities | $143M | $135M | $171M | $109M | $112M | $116M | $82M | $72M | $80M | $100M | · | $96M | $97M | $82M | · | $60M | |
| Capital Leases | $10M | $10M | $11M | $10M | $11M | $11M | $12M | $12M | $3M | $4M | · | $4M | $5M | $5M | · | $6M | |
| Total Liabilities | $800M | $804M | $843M | $539M | $467M | $469M | $473M | $674M | $670M | $711M | · | $572M | $574M | $554M | · | $532M | |
| Long-term Debt | $319M | $319M | $355M | $110M | $36M | $36M | $36M | $228M | $228M | $264M | · | $273M | $274M | $274M | · | $273M | |
| Common Stock | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | · | $3M | $3M | $3M | · | $3M | |
| Retained Earnings | $-3.23B | $-3.21B | $-3.20B | $-3.18B | $-3.19B | $-3.19B | $-3.20B | $-3.21B | $-3.22B | $-3.22B | · | $-3.23B | $-3.23B | $-3.23B | · | $-3.20B | |
| AOCI | $-19.0K | $-4.0K | $115.0K | $137.0K | $1M | $1M | $1M | $588.0K | · | · | · | $443.0K | $443.0K | · | · | $-1M | |
| Stockholders' Equity | $-67M | $-59M | $-51M | $-45M | $-55M | $-59M | $-79M | $-210M | $-226M | $-230M | $-246M | $-252M | $-260M | $-255M | $-251M | $-238M | |
| Liabilities + Equity | $732M | $744M | $792M | $495M | $412M | $410M | $394M | $464M | $444M | $481M | · | $320M | $313M | $298M | · | $294M | |
| Shares Outstanding | 309,911,682 | 308,907,331 | 307,832,587 | 307,027,189 | 306,332,133 | 303,918,969 | 302,959,782 | 275,775,038 | 274,467,247 | 270,801,781 | · | 269,543,539 | 268,235,145 | 264,278,760 | · | 263,156,165 |
Flujo de Efectivo 11
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $6M | $6M | $6M | $2M | $2M | $2M | $2M | $2M | $2M | $1M | $1M | $1M | $1M | $1M | $1M | $-427.0K | |
| Stock-based Comp | $10M | $6M | $7M | $4M | $8M | $5M | $6M | $5M | $6M | $4M | $4M | $5M | $6M | $4M | $3M | $4M | |
| Amort. of Intangibles | $4M | $4M | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Operating Cash Flow | $-18M | $-5M | $-8M | $24M | $9M | $-6M | $23M | $9M | $4M | $7M | $22M | $9M | $3M | $1M | $-2M | $-28M | |
| CapEx | $5M | $2M | $2M | $1M | $1M | $330.0K | $3M | $1M | $3M | $2M | $6M | $11M | $17M | $8M | $5M | $271.0K | |
| Investing Cash Flow | $18M | $19M | $-292M | $-25M | $6M | $6M | $48M | $-41M | $-55M | $-48M | $-8M | $-12M | $4M | $14M | $15M | $27M | |
| Financing Cash Flow | $559.0K | $-35M | $247M | $72M | $-6M | $1M | $-87M | $-2M | $-45M | $-3M | $142M | $-283.0K | $-6M | $1M | $3M | $20M | |
| Net Change in Cash | $97.0K | $-22M | $-53M | $70M | $10M | $975.0K | $-16M | $-34M | $-96M | $-45M | $155M | $-3M | $315.0K | $16M | $15M | $19M | |
| Taxes Paid | $753.0K | $63.0K | $549.0K | $80.0K | $869.0K | $207.0K | $2M | $236.0K | · | · | · | · | · | · | · | · | |
| Free Cash Flow | · | $-7M | · | · | · | $-7M | · | · | · | $4M | · | · | · | $-7M | · | · | |
| Levered FCF | · | · | · | · | · | · | · | · | · | $2M | · | · | · | $-10M | · | · |
Rentabilidad 7
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | · | -1.8% | · | 23.0% | 6.9% | 28.4% | · | 18.2% | 22.9% | 25.2% | · | 9.9% | 3.5% | -14.8% | · | -29.3% | |
| Net Margin | · | -18.4% | · | 9.7% | 0.87% | 16.8% | · | 16.5% | -2.8% | 16.0% | · | 3.4% | -10.8% | -24.1% | · | -44.0% | |
| Pretax Margin | · | -18.1% | · | 9.5% | 1.2% | 17.4% | · | 18.4% | -2.3% | 16.4% | · | 3.4% | -10.8% | -24.1% | · | -44.0% | |
| EBITDA Margin | · | -1.8% | · | 23.0% | 6.9% | 28.4% | · | 18.2% | 22.9% | 25.2% | · | 9.9% | 3.5% | -14.8% | · | -29.3% | |
| ROA | · | -2.9% | · | 1.7% | 0.16% | 2.9% | · | 2.9% | -0.53% | 2.7% | · | 0.56% | -1.8% | -3.2% | · | -5.4% | |
| ROE | · | 28.2% | · | -6.3% | -0.48% | -9.1% | · | -5.0% | 0.83% | -4.4% | · | -0.70% | 2.1% | 4.0% | · | 6.8% | |
| ROIC | · | 2.9% | · | -43.5% | -6.8% | -36.8% | · | -5.5% | -8.8% | -7.1% | · | -2.0% | -0.66% | 2.4% | · | · |
Liquidez y Solvencia 3
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.7 | 1.9 | · | 3.3 | 2.5 | 2.4 | · | 4.5 | 4.1 | 3.8 | · | 2.3 | 2.4 | 2.7 | · | 3.7 | |
| Quick Ratio | · | 1.2 | · | 2.5 | 1.8 | 1.8 | · | 3.7 | 3.4 | 3.2 | · | 1.7 | 1.8 | 2.3 | · | 3.2 | |
| Interest Coverage | · | · | · | · | · | · | · | · | 2.7 | 6.5 | · | 1.8 | 0.3 | -2.5 | · | · |
Eficiencia 3
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.1 | · | 0.1 | |
| Inventory Turnover | 0.4 | 0.2 | · | 0.2 | 0.2 | 0.1 | · | 0.1 | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.4 | · | 0.4 | |
| Receivables Turnover | 3.1 | 3.2 | · | 4.6 | 3.0 | 3.2 | · | 3.5 | 2.8 | 3.3 | · | 2.3 | 2.3 | 2.8 | · | 2.0 |
Valoración (TTM) 9
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $358M | $327M | · | $307M | $297M | $287M | · | $260M | $239M | $207M | · | $173M | $141M | $104M | · | $86M | |
| Net Income TTM | $-27M | $5M | · | $33M | $23M | $33M | · | $22M | $5M | $-3M | · | $-28M | $-59M | $-79M | · | $-74M | |
| Market Cap | $1.32B | $757M | · | $1.65B | $1.15B | $1.53B | · | $1.73B | $1.43B | $1.23B | · | $1.11B | $1.09B | $1.08B | · | $813M | |
| P/E | -53.2 | 122.5 | · | 48.8 | 53.4 | 45.7 | · | 78.6 | 261.0 | -453.0 | · | -37.5 | -17.7 | -13.2 | · | -10.7 | |
| P/S | 3.7 | 2.3 | · | 5.4 | 3.9 | 5.3 | · | 6.7 | 6.0 | 5.9 | · | 6.4 | 7.7 | 10.4 | · | 9.5 | |
| P/B | -19.6 | -12.8 | · | -37.0 | -20.8 | -26.1 | · | -8.3 | -6.3 | -5.3 | · | -4.4 | -4.2 | -4.2 | · | -3.4 | |
| P / Cash Flow | · | -141.1 | · | · | · | -239.7 | · | · | · | 183.0 | · | · | · | 937.3 | · | · | |
| P / FCF | · | -104.5 | · | · | · | -227.9 | · | · | · | 285.6 | · | · | · | -151.4 | · | · | |
| Earnings Yield | -1.9% | 0.82% | · | 2.1% | 1.9% | 2.2% | · | 1.3% | 0.38% | -0.22% | · | -2.7% | -5.7% | -7.6% | · | -9.4% |
Estados Financieros Estado de resultados, balance general, flujo de caja — anual, últimos 5 años
Estado de resultados
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Ingresos | $349M | $286M | $199M | $100M | $75M |
| Margen Operativo % | 11.1% | 25.4% | 4.4% | -64.3% | -62.3% |
| Beneficio neto | $6M | $28M | $-12M | $-87M | $-81M |
| EPS Diluido | $0.02 | $0.10 | $-0.04 | $-0.34 | $-0.32 |
Balance general
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Ratio corriente | 1.7 | 3.3 | 3.6 | 3.5 | 4.5 |
| Ratio Rápido | 1.2 | 2.6 | 3.0 | 2.8 | 4.3 |
Flujo de Efectivo
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Flujo de caja libre | $14M | $33M | $-8M | $-88M | $-73M |
Últimas noticias Noticias recientes que mencionan a esta empresa
- Wells Fargo Calls MannKind Corporation (MNKD)’s Commercial Potential a “Show-Me Story”
- MannKind (MNKD) Advances Clinical Trials for Inhaled IPF Therapy
- H.C. Wainwright y Wells Fargo elevan los objetivos de precio de MannKind (MNKD)
- ¿Es MannKind Corporation (MNKD) una de las acciones penny más populares en Robinhood para comprar?
Señales de trading Señales recientes de compra/venta con precio de entrada y ratio riesgo/recompensa
Mis Métricas Tu lista de seguimiento personal — filas seleccionadas de Fundamentales Completos
📊
Elige las métricas que te importan — haz clic en el ➕ junto a cualquier fila en Fundamentales Completos arriba.
Tu selección se guarda y te sigue en todos los tickers.
Propietarios institucionales (13F) 271 declarantes · $560.6M total · A fecha de 30 de junio de 2026
Instituciones que informan tener esta acción en su Formulario 13F trimestral de la SEC. Solo posiciones largas; un solo presentador puede aparecer dos veces para tramos de opciones separados. Las patas de put/call de compensación grandes suelen reflejar la creación de mercado o el inventario cubierto, no la convicción direccional.
Actividad institucional — Q2 2026 vs trimestre anterior
| Nuevas posiciones | Posiciones cerradas | Aumentado | Disminuido | Cambio neto de acciones |
|---|---|---|---|---|
| 55 (+12 vs trimestre anterior) | 37 (-11 vs trimestre anterior) | 93 (+10 vs trimestre anterior) | 61 (-8 vs trimestre anterior) | +24.2M |
Comparado con Q1 2026. Las presentaciones del Formulario 13F de la SEC vencen dentro de los 45 días posteriores al final del trimestre, más un pequeño margen para los presentadores tardíos; los trimestres que aún se encuentran dentro de esa ventana se omiten en favor del par más reciente completamente reportado.
| Institución | Valor | Acciones | % de 13F rastreadas | Tipo |
|---|---|---|---|---|
| Rubric Capital Management LP | $76 680 000 | 18 000 000 | 13,68% | Acciones |
| STATE STREET CORP | $68 901 423 | 16 174 043 | 12,29% | Acciones |
| VANGUARD CAPITAL MANAGEMENT LLC | $56 101 610 | 13 169 392 | 10,01% | Acciones |
| GEODE CAPITAL MANAGEMENT, LLC | $29 027 881 | 6 812 460 | 5,18% | Acciones |
| Frazier Life Sciences Management, L.P. | $28 116 000 | 6 600 000 | 5,01% | Acciones |
| Deep Track Capital, LP | $25 560 000 | 6 000 000 | 4,56% | Acciones |
| WELLINGTON MANAGEMENT GROUP LLP | $23 099 232 | 5 422 355 | 4,12% | Acciones |
| 180 WEALTH ADVISORS, LLC | $21 126 835 | 4 959 351 | 3,77% | Acciones |
| FMR LLC | $17 455 563 | 4 097 550 | 3,11% | Acciones |
| TSP Capital Management Group, LLC | $16 923 596 | 3 972 675 | 3,02% | Acciones |
| BRAIDWELL LP | $14 732 908 | 3 458 429 | 2,63% | Acciones |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $12 789 240 | 3 002 169 | 2,28% | Acciones |
| VANGUARD GROUP INC | $11 888 249 | 2 096 693 | 2,12% | Acciones |
| TWO SIGMA INVESTMENTS, LP | $11 475 213 | 2 693 712 | 2,05% | Acciones |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $11 070 577 | 2 598 727 | 1,97% | Acciones |
| VANGUARD FIDUCIARY TRUST CO | $9 358 279 | 2 196 779 | 1,67% | Acciones |
| BANK OF AMERICA CORP /DE/ | $8 689 749 | 2 039 847 | 1,55% | Acciones |
| GOLDMAN SACHS GROUP INC | $6 332 618 | 1 486 530 | 1,13% | Acciones |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $5 030 221 | 1 180 803 | 0,90% | Acciones |
| BlackRock, Inc. | $4 766 748 | 1 118 955 | 0,85% | Acciones |
| DIMENSIONAL FUND ADVISORS LP | $4 486 321 | 1 053 127 | 0,80% | Acciones |
| Caption Management, LLC | $4 260 000 | 1 000 000 | 0,76% | Opción de venta |
| J. Goldman & Co LP | $3 478 669 | 816 589 | 0,62% | Acciones |
| WELLS FARGO & COMPANY/MN | $3 473 987 | 815 490 | 0,62% | Acciones |
| SCOPIA CAPITAL MANAGEMENT LP | $2 960 534 | 694 961 | 0,53% | Acciones |
| Balyasny Asset Management L.P. | $2 914 296 | 684 107 | 0,52% | Acciones |
| TWO SIGMA ADVISERS, LP | $2 897 166 | 510 964 | 0,52% | Acciones |
| VICTORY CAPITAL MANAGEMENT INC | $2 771 407 | 650 565 | 0,49% | Acciones |
| Swiss National Bank | $2 502 324 | 587 400 | 0,45% | Acciones |
| STATE OF WISCONSIN INVESTMENT BOARD | $2 177 052 | 511 045 | 0,39% | Acciones |
| JACOBS LEVY EQUITY MANAGEMENT, INC | $2 106 540 | 494 493 | 0,38% | Acciones |
| 1492 Capital Management LLC | $2 052 136 | 481 722 | 0,37% | Acciones |
| Mariner, LLC | $2 020 189 | 474 236 | 0,36% | Acciones |
| MILLENNIUM MANAGEMENT LLC | $1 836 597 | 431 126 | 0,33% | Acciones |
| Schonfeld Strategic Advisors LLC | $1 774 216 | 416 483 | 0,32% | Acciones |
| Squarepoint Ops LLC | $1 759 644 | 413 062 | 0,31% | Acciones |
| Jefferies Financial Group Inc. | $1 694 202 | 397 700 | 0,30% | Acciones |
| ExodusPoint Capital Management, LP | $1 666 261 | 391 141 | 0,30% | Acciones |
| JANE STREET GROUP, LLC | $1 658 418 | 389 300 | 0,30% | Opción de compra |
| Man Group plc | $1 624 023 | 381 226 | 0,29% | Acciones |
| RHUMBLINE ADVISERS | $1 604 647 | 376 681 | 0,29% | Acciones |
| IEQ CAPITAL, LLC | $1 544 607 | 362 584 | 0,28% | Acciones |
| CITIGROUP INC | $1 499 243 | 351 935 | 0,27% | Acciones |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $1 423 692 | 334 200 | 0,25% | Opción de venta |
| Bank of New York Mellon Corp | $1 422 222 | 333 855 | 0,25% | Acciones |
| Caption Management, LLC | $1 414 231 | 331 979 | 0,25% | Acciones |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $1 359 221 | 319 066 | 0,24% | Acciones |
| ALPS ADVISORS INC | $1 330 615 | 312 351 | 0,24% | Acciones |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $1 216 230 | 285 500 | 0,22% | Opción de compra |
| MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | $1 029 075 | 241 567 | 0,18% | Acciones |
| BARCLAYS PLC | $1 029 062 | 241 564 | 0,18% | Acciones |
| Rafferty Asset Management, LLC | $1 008 640 | 236 770 | 0,18% | Acciones |
| BNP PARIBAS FINANCIAL MARKETS | $1 002 715 | 235 379 | 0,18% | Acciones |
| Aaron Wealth Advisors LLC | $1 000 878 | 234 948 | 0,18% | Acciones |
| HSBC HOLDINGS PLC | $998 560 | 230 881 | 0,18% | Acciones |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $930 294 | 379 712 | 0,17% | Acciones |
| CITADEL ADVISORS LLC | $928 680 | 218 000 | 0,17% | Opción de compra |
| CITADEL ADVISORS LLC | $898 860 | 211 000 | 0,16% | Opción de venta |
| Bruce & Co., Inc. | $831 011 | 195 073 | 0,15% | Acciones |
| VANGUARD ASSET MANAGEMENT, Ltd | $775 060 | 181 939 | 0,14% | Acciones |
| MetLife Investment Management, LLC | $766 442 | 179 916 | 0,14% | Acciones |
| FRANKLIN RESOURCES INC | $755 021 | 177 235 | 0,13% | Acciones |
| Stonepine Capital Management, LLC | $750 000 | 250 000 | 0,13% | Opción de compra |
| UBS Group AG | $715 978 | 168 070 | 0,13% | Acciones |
| ALLIANCEBERNSTEIN L.P. | $693 375 | 283 010 | 0,12% | Acciones |
| MORGAN STANLEY | $651 282 | 152 883 | 0,12% | Acciones |
| TUDOR INVESTMENT CORP ET AL | $640 657 | 150 389 | 0,11% | Acciones |
| RAYMOND JAMES FINANCIAL INC | $632 009 | 148 359 | 0,11% | Acciones |
| WEALTH ENHANCEMENT ADVISORY SERVICES, LLC | $613 437 | 171 372 | 0,11% | Acciones |
| Jain Global LLC | $604 673 | 141 942 | 0,11% | Acciones |
| KING LUTHER CAPITAL MANAGEMENT CORP | $590 457 | 138 605 | 0,11% | Acciones |
| Susquehanna Portfolio Strategies, LLC | $574 538 | 134 868 | 0,10% | Acciones |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $570 354 | 133 886 | 0,10% | Acciones |
| MERCER GLOBAL ADVISORS INC /ADV | $557 723 | 130 921 | 0,10% | Acciones |
| PROFUND ADVISORS LLC | $517 726 | 121 532 | 0,09% | Acciones |
| Invesco Ltd. | $512 389 | 120 279 | 0,09% | Acciones |
| Vanguard Global Advisers, LLC | $509 833 | 119 679 | 0,09% | Acciones |
| KLP KAPITALFORVALTNING AS | $491 604 | 115 400 | 0,09% | Acciones |
| Gotham Asset Management, LLC | $452 463 | 106 212 | 0,08% | Acciones |
| State of New Jersey Common Pension Fund D | $403 171 | 94 641 | 0,07% | Acciones |
| State of Wyoming | $403 149 | 94 636 | 0,07% | Acciones |
| Police & Firemen's Retirement System of New Jersey | $386 834 | 90 806 | 0,07% | Acciones |
| Amundi | $374 310 | 87 866 | 0,07% | Acciones |
| Zurcher Kantonalbank (Zurich Cantonalbank) | $373 478 | 87 671 | 0,07% | Acciones |
| NEW YORK STATE COMMON RETIREMENT FUND | $359 966 | 84 499 | 0,06% | Acciones |
| ARIZONA STATE RETIREMENT SYSTEM | $344 050 | 80 763 | 0,06% | Acciones |
| Mitsubishi UFJ Asset Management Co., Ltd. | $338 155 | 79 379 | 0,06% | Acciones |
| Aquatic Capital Management LLC | $335 300 | 78 709 | 0,06% | Acciones |
| Rockefeller Capital Management L.P. | $332 996 | 78 168 | 0,06% | Acciones |
| Vanguard Investments Australia, Ltd. | $314 929 | 73 927 | 0,06% | Acciones |
| JANUS HENDERSON GROUP PLC | $313 658 | 127 763 | 0,06% | Acciones |
| STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM | $312 203 | 73 287 | 0,06% | Acciones |
| Sequoia Financial Advisors, LLC | $296 935 | 69 703 | 0,05% | Acciones |
| INTECH INVESTMENT MANAGEMENT LLC | $284 653 | 66 820 | 0,05% | Acciones |
| COMMONWEALTH EQUITY SERVICES, LLC | $280 421 | 65 827 | 0,05% | Acciones |
| China Universal Asset Management Co., Ltd. | $262 714 | 61 670 | 0,05% | Acciones |
| LPL Financial LLC | $260 060 | 61 047 | 0,05% | Acciones |
| SIMPLEX TRADING, LLC | $258 790 | 60 749 | 0,05% | Acciones |
| Cetera Investment Advisers | $241 546 | 56 701 | 0,04% | Acciones |
| Painted Porch Advisors LLC | $227 620 | 53 432 | 0,04% | Acciones |
Informantes de la empresa 43 insiders · 27 directivos · 18 consejeros
| Insider | Rol | Última actividad | Acciones en propiedad | Compras 12m | Ventas 12m | Neto 12m |
|---|---|---|---|---|---|---|
| Michael Castagna | Chief Executive Officer | 15 de julio de 2026 M | 2 433 779 | 1 | 4 | $-990 292 |
| Hakan Edstrom | President & CEO | 27 de agosto de 2015 A | 1 114 340 | 0 | 0 | $0 |
| Christopher B Prentiss | Chief Financial Officer | 15 de julio de 2026 F | 318 668 | 0 | 0 | $0 |
| Juergen Martens | Corporate VP and COO | 27 de agosto de 2015 A | 106 539 | 0 | 0 | $0 |
| Dominic Marasco | Pres, Endocrine Business Unit | 15 de julio de 2026 F | 343 398 | 0 | 0 | $0 |
| Sanjay R Singh | EVP Technical Operations | 15 de julio de 2026 M | 478 966 | 0 | 1 | $-94 448 |
| Stuart A Tross | Chief People & Workpl Officer | 15 de julio de 2026 M | 1 058 142 | 0 | 2 | $-548 528 |
| David Thomson | EVP Genl Counsel & Secretary | 15 de julio de 2026 M | 797 554 | 0 | 3 | $-930 755 |
| Ajay Ahuja | Chief Medical Officer | 23 de marzo de 2026 A | 318 200 | 0 | 0 | $0 |
| Lauren M Sabella | EVP Operations | 15 de julio de 2025 F | 349 841 | 0 | 0 | $0 |
| Burkhard Blank | EVP Chief Medical Officer | 15 de julio de 2025 F | 460 791 | 0 | 0 | $0 |
| Joseph Kocinsky | Chief Technology Officer | 27 de agosto de 2022 F | 745 233 | 0 | 0 | $0 |
| Alejandro Galindo | EVP Endocrine Business Unit | 28 de febrero de 2022 A | 576 690 | 0 | 0 | $0 |
| Rosabel Realica Alinaya | VP, IR & Treasury | 27 de agosto de 2020 A | 167 119 | 0 | 0 | $0 |
| David M Kendall | Chief Medical Officer | 31 de julio de 2020 P | 41 059 | 0 | 0 | $0 |
| Patrick Mccauley | Chief Commercial Officer | 25 de febrero de 2020 A | 83 972 | 0 | 0 | $0 |
| Courtney Barton | Chief Compl & Privacy Officer | 31 de julio de 2019 P | 29 584 | 0 | 0 | $0 |
| Elizabeth Garrett Ingram | Chief Marketing Officer | 14 de mayo de 2019 A | 43 012 | 0 | 0 | $0 |
| Raymond W. Urbanski | Corp VP, CMO | 10 de agosto de 2017 S | 2 924 | 0 | 0 | $0 |
| Linda A Adreveno | Sr. VP, HR | 18 de febrero de 2016 A | 92 200 | 0 | 0 | $0 |
| Alfred E Mann | Executive Chairman | 22 de agosto de 2015 F | 1 005 990 | 0 | 0 | $0 |
| Diane Palumbo | Vice President, Human Resource | 23 de febrero de 2015 F | 50 624 | 0 | 0 | $0 |
| Peter C Richardson | Chief Scientific Officer | 3 de marzo de 2012 F | 133 611 | 0 | 0 | $0 |
| Richard L Anderson | Corporate VP | 16 de noviembre de 2008 F | 204 401 | 0 | 0 | $0 |
| John R. Riesenberger | VP & Chief Commercial Officer | 13 de agosto de 2008 A | 14 650 | 0 | 0 | $0 |
| Dan Burns | VP & President, MKBP | 8 de diciembre de 2006 A | 14 800 | 0 | 0 | $0 |
| Wendell W Cheatham | VP, Medical & Reg Affairs | 19 de agosto de 2004 A | 300 | 0 | 0 | $0 |
| Sabrina Kay | Consejero | 20 de mayo de 2026 A | 265 600 | 0 | 0 | $0 |
| Jennifer Grancio | Consejero | 20 de mayo de 2026 A | 244 815 | 0 | 0 | $0 |
| James Samuel Shannon | Consejero | 20 de mayo de 2026 A | 64 635 | 0 | 0 | $0 |
| Michael A Friedman | Consejero | 20 de mayo de 2026 A | 47 500 | 0 | 0 | $0 |
| Anthony C Hooper | Consejero | 20 de mayo de 2026 A | 236 153 | 0 | 0 | $0 |
| Christine Mundkur | Consejero | 20 de mayo de 2026 A | 254 493 | 0 | 0 | $0 |
| Ronald J Consiglio | Consejero | 20 de mayo de 2026 A | 132 342 | 0 | 0 | $0 |
| Kent Kresa | Consejero | 15 de mayo de 2024 A | 274 541 | 0 | 0 | $0 |
| Henry L Nordhoff | Consejero | 14 de mayo de 2019 A | 103 426 | 0 | 0 | $0 |
| David Maccallum | Consejero | 16 de mayo de 2018 A | 114 790 | 0 | 0 | $0 |
| Matthew J Pfeffer | Consejero | 28 de agosto de 2017 F | 81 961 | 0 | 0 | $0 |
| Abraham E Cohen | Consejero | 17 de agosto de 2012 S | 56 424 | 0 | 0 | $0 |
| Heather Hay Murren | Consejero | 13 de agosto de 2008 A | 10 100 | 0 | 0 | $0 |
| Kathleen Connell | Consejero | 25 de mayo de 2006 A | — | 0 | 0 | $0 |
| Llew Keltner | Consejero | 25 de mayo de 2006 A | — | 0 | 0 | $0 |
| Steven B. Binder | — | 7 de agosto de 2026 S | 785 867 | 0 | 3 | $-427 369 |
Informantes de las presentaciones SEC Form 3/4/5; neto = solo P/S de mercado abierto
Activistas y propietarios del %+ 5 2 tenencias
Inversores que presentaron el Anexo 13D de la SEC — propiedad beneficiosa superior al % 5 con la intención de influir en el emisor (participaciones activistas, campañas de la junta directiva, M&A). Cada fila muestra el estado conocido más reciente de la posición de ese declarante.
| Declarante | Presentado | Participación | Estado | Propósito | Presentación |
|---|---|---|---|---|---|
| Alfred E. Mann, Alfred E. Mann Living Trust, Biomed Partners, LLC, Minimed Infusion, Inc., The Mann Group LLC ×2 presentaciones | 10 de julio de 2012 | — | Presentación inicial | Inversión pasiva | SEC |
| Persona informante no revelada, Persona informante no revelada, Persona informante no revelada, Persona informante no revelada | 31 de enero de 2006 | — | Presentación inicial | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Propiedad de ETFs Mantenido por 41 ETFs
El peso refleja solo las tenencias directas de acciones (N-PORT); los fondos apalancados o basados en derivados pueden tener exposición adicional a swaps no mostrada.
| Fondo | Ponderación | Unidades | A fecha de | Fuente |
|---|---|---|---|---|
| RNIN · EA Series Trust | 1,43% | 773 251 NS | 30 de abril de 2026 | N-PORT |
| SBIO · ALPS ETF Trust | 0,74% | 317 578 NS | 31 de mayo de 2026 | N-PORT |
| QQQS · Invesco Exchange-Traded Fund Trust … | 0,54% | 29 662 SH | 8 de agosto de 2026 | Diario |
| AGNG · Global X Funds | 0,46% | 98 947 NS | 31 de mayo de 2026 | N-PORT |
| LABU · Direxion Shares ETF Trust | 0,34% | 625 921 NS | 30 de abril de 2026 | N-PORT |
| GINN · Goldman Sachs ETF Trust | 0,11% | 64 525 NS | 31 de mayo de 2026 | N-PORT |
| IBB · iShares Trust | 0,09% | 2 170 137 SH | 8 de agosto de 2026 | Diario |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,09% | 16 814 SH | 8 de agosto de 2026 | Diario |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,08% | 330 117 SH | 8 de agosto de 2026 | Diario |
| IWO · iShares Trust | 0,07% | 2 772 931 SH | 8 de agosto de 2026 | Diario |
| ESML · iShares Trust | 0,06% | 449 515 SH | 8 de agosto de 2026 | Diario |
| BIB · ProShares Trust | 0,06% | 11 389 NS | 31 de mayo de 2026 | N-PORT |
| BBSC · J.P. Morgan Exchange-Traded Fund Tr… | 0,04% | 114 273 NS | 30 de abril de 2026 | N-PORT |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,04% | 1 771 496 SH | 8 de agosto de 2026 | Diario |
| IWM · iShares Trust | 0,04% | 7 830 029 SH | 8 de agosto de 2026 | Diario |
| ISCG · iShares Trust | 0,04% | 94 032 SH | 8 de agosto de 2026 | Diario |
| ITWO · ProShares Trust | 0,03% | 14 400 NS | 31 de mayo de 2026 | N-PORT |
| RSSL · Global X Funds | 0,03% | 132 607 NS | 30 de abril de 2026 | N-PORT |
| SCHA · SCHWAB STRATEGIC TRUST | 0,02% | 1 466 402 NS | 31 de mayo de 2026 | N-PORT |
| GSSC · Goldman Sachs ETF Trust | 0,02% | 61 465 NS | 31 de mayo de 2026 | N-PORT |
| VHT · VANGUARD WORLD FUND | 0,02% | 874 372 SH | 8 de agosto de 2026 | Diario |
| ISCB · iShares Trust | 0,02% | 13 557 SH | 8 de agosto de 2026 | Diario |
| UWM · ProShares Trust | 0,02% | 11 261 NS | 31 de mayo de 2026 | N-PORT |
| FHLC · FIDELITY COVINGTON TRUST | 0,01% | 135 688 NS | 30 de abril de 2026 | N-PORT |
| DFAS · Dimensional ETF Trust | 0,01% | 638 128 NS | 30 de abril de 2026 | N-PORT |
| URTY · ProShares Trust | 0,01% | 11 390 NS | 31 de mayo de 2026 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | 0,01% | 3 543 398 SH | 8 de agosto de 2026 | Diario |
| WSML · iShares Trust | 0,01% | 16 464 SH | 8 de agosto de 2026 | Diario |
| MSSM · MORGAN STANLEY PATHWAY FUNDS | 0,01% | 12 000 NS | 31 de mayo de 2026 | N-PORT |
| HDG · ProShares Trust | 0,01% | 286 NS | 31 de mayo de 2026 | N-PORT |
| DFAC · Dimensional ETF Trust | 0,00% | 452 118 NS | 30 de abril de 2026 | N-PORT |
| DCOR · Dimensional ETF Trust | 0,00% | 27 701 NS | 30 de abril de 2026 | N-PORT |
| AVUQ · AMERICAN CENTURY ETF TRUST | 0,00% | 1 330 NS | 31 de mayo de 2026 | N-PORT |
| ITOT · iShares Trust | 0,00% | 465 445 SH | 8 de agosto de 2026 | Diario |
| SCHB · SCHWAB STRATEGIC TRUST | 0,00% | 196 006 NS | 31 de mayo de 2026 | N-PORT |
| IWV · iShares Trust | 0,00% | 83 220 SH | 8 de agosto de 2026 | Diario |
| TILT · FlexShares Trust | 0,00% | 10 345 NS | 30 de abril de 2026 | N-PORT |
| DFUS · Dimensional ETF Trust | 0,00% | 32 093 NS | 30 de abril de 2026 | N-PORT |
| DFAU · Dimensional ETF Trust | 0,00% | 14 557 NS | 30 de abril de 2026 | N-PORT |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 9 327 332 SH | 8 de agosto de 2026 | Diario |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,00% | 26 184 SH | 8 de agosto de 2026 | Diario |